Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2019)
FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatmentofadultswithhigh-riskacutemyeloidleukemia
P. Kottaridis, R. Gale, S. Langabeer, M. Frew, D. Bowen, D. Linch (2002)
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.Blood, 100 7
Liqing Jin, Kristin Hope, Q. Zhai, F. Smadja-joffe, J. Dick (2006)
Targeting of CD44 eradicates human acute myeloid leukemic stem cellsNature Medicine, 12
V. Yu, D. Scadden (2016)
Hematopoietic Stem Cell and Its Bone Marrow Niche.Current topics in developmental biology, 118
L. Shlush, Amanda Mitchell, Lawrence Heisler, Sagi Abelson, Stanley Ng, Aaron Trotman-Grant, Jessie Medeiros, Abilasha Rao-Bhatia, Ivana Jaciw-Zurakowsky, René Marke, Jessica Mcleod, M. Doedens, Gary Bader, V. Voisin, Changjiang Xu, J. McPherson, T. Hudson, Jean Wang, M. Minden, J. Dick (2017)
Tracing the origins of relapse in acute myeloid leukaemia to stem cellsNature, 547
Luke Fletcher, S. Joshi, E. Traer (2020)
Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to DateCancer Management and Research, 12
Jacqueline Cloos, B. Goemans, C. Hess, J. Oostveen, Q. Waisfisz, S. Corthals, D. Lange, Nancy Boeckx, Karel Hählen, Dirk Reinhardt, U. Creutzig, G. Schuurhuis, C. Zwaan, G. Kaspers (2006)
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samplesLeukemia, 20
K. Metzeler, T. Herold, M. Rothenberg-Thurley, S. Amler, M. Sauerland, D. Görlich, S. Schneider, N. Konstandin, A. Dufour, Kathrin Bräundl, B. Ksienzyk, E. Zellmeier, L. Hartmann, P. Greif, M. Fiegl, M. Subklewe, S. Bohlander, U. Krug, A. Faldum, W. Berdel, B. Wörmann, T. Büchner, W. Hiddemann, J. Braess, K. Spiekermann (2016)
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.Blood, 128 5
C. Thiede, C. Steudel, B. Mohr, M. Schaich, U. Schäkel, U. Platzbecker, M. Wermke, M. Bornhäuser, M. Ritter, A. Neubauer, G. Ehninger, T. Illmer (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.Blood, 99 12
SM Devine, K Owzar, W Blum (2015)
Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced‐intensity conditioning regimen: results from cancer and leukemia group B 100103 (alliance for clinical trials in oncology)/blood and marrow transplant clinical trial network 0502, 33
Sun Kim, Jeen-Woo Park (2003)
Cellular Defense against Singlet Oxygen-induced Oxidative Damage by Cytosolic NADP + -dependent Isocitrate DehydrogenaseFree Radical Research, 37
E. Lagadinou, Alexander Šach, K. Callahan, R. Rossi, S. Neering, Mohammad Minhajuddin, J. Ashton, Shanshan Pei, Valerie Grose, K. O'Dwyer, J. Liesveld, P. Brookes, M. Becker, C. Jordan (2013)
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.Cell stem cell, 12 3
A. Perl, J. Altman, J. Cortes, Catherine Smith, M. Litzow, M. Baer, D. Claxton, H. Erba, S. Gill, S. Goldberg, J. Jurcic, R. Larson, Chaofeng Liu, E. Ritchie, G. Schiller, A. Spira, S. Strickland, R. Tibes, C. Ustun, E. Wang, R. Stuart, C. Röllig, A. Neubauer, G. Martinelli, E. Bahceci, M. Levis (2017)
Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 StudyThe Lancet. Oncology, 18
A. Perl, G. Martinelli, J. Cortes, A. Neubauer, E. Berman, S. Paolini, P. Montesinos, M. Baer, R. Larson, C. Ustun, F. Fabbiano, H. Erba, A. Stasi, R. Stuart, R. Olin, M. Kasner, F. Ciceri, W. Chou, N. Podoltsev, C. Récher, Hisayuki Yokoyama, N. Hosono, S. Yoon, Je-Hwan Lee, T. Pardee, A. Fathi, Chaofeng Liu, N. Hasabou, Xuan Liu, E. Bahceci, M. Levis (2019)
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.The New England journal of medicine, 381 18
Kristin Hope, Liqing Jin, J. Dick (2004)
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacityNature Immunology, 5
P. Blombery, M. Anderson, Jia-Nan Gong, R. Thijssen, R. Birkinshaw, E. Thompson, Charis Teh, Tamia Nguyen, Zhen Xu, C. Flensburg, T. Lew, I. Majewski, D. Gray, D. Westerman, C. Tam, J. Seymour, P. Czabotar, D. Huang, A. Roberts (2018)
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.Cancer discovery, 9 3
K. Norsworthy, Lola Luo, Vicky Hsu, R. Gudi, Sarah Dorff, D. Przepiorka, A. Deisseroth, Y. Shen, Christopher Sheth, R. Charlab, G. Williams, Kirsten Goldberg, A. Farrell, R. Pazdur (2019)
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 MutationClinical Cancer Research, 25
(2022)
OUP accepted manuscriptStem Cells Translational Medicine
C. Dinardo, B. Jonas, V. Pullarkat, M. Thirman, Jacqueline Garcia, A. Wei, M. Konopleva, H. Döhner, A. Letai, P. Fenaux, E. Koller, V. Havelange, B. Leber, J. Esteve, Jianxiang Wang, V. Pejsa, R. Hájek, K. Porkka, Á. Illés, D. Lavie, R. Lemoli, Kazuhito Yamamoto, S. Yoon, J. Jang, S. Yeh, M. Turgut, W. Hong, Ying Zhou, J. Potluri, K. Pratz (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.The New England journal of medicine, 383 7
S. Knipp, Barbara Hildebrand, A. Kündgen, A. Giagounidis, G. Kobbe, R. Haas, C. Aul, N. Gattermann, U. Germing (2007)
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypesCancer, 110
R. Ma, C. Yun (2018)
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.Biochemical and biophysical research communications, 503 4
D. Pollyea, K. Pratz, B. Jonas, A. Letai, V. Pullarkat, A. Wei, M. Konopleva, C. Récher, O. Frankfurt, D. Rizzieri, T. Xu, Monique Dail, B. Chyla, J. Potluri, C. Dinardo (2018)
Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive TherapyBlood
J. Watts, M. Baer, Jay Yang, T. Prebet, Sangmin Lee, G. Schiller, S. Dinner, A. Pigneux, P. Montesinos, E. Wang, K. Seiter, A. Wei, S. Botton, M. Arnán, W. Donnellan, A. Schwarer, C. Récher, B. Jonas, P. Ferrell, C. Marzac, P. Kelly, J. Sweeney, S. Forsyth, Sylvie Guichard, J. Brevard, P. Henrick, Hesham Mohamed, Jordi Cortés (2022)
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.The Lancet. Haematology
Ping Chen, Q. Jin, Q. Fu, Pei-Dong You, Xi Jiang, Q. Yuan, Huifang Huang (2016)
Induction of Multidrug Resistance of Acute Myeloid Leukemia Cells by Cocultured Stromal Cells via Upregulation of the PI3K/Akt Signaling PathwayOncology Research, 24
Xiaochuan Yang, Amy Sexauer, M. Levis (2014)
Bone marrow stroma‐mediated resistance to FLT3 inhibitors in FLT3‐ITD AML is mediated by persistent activation of extracellular regulated kinaseBritish Journal of Haematology, 164
V. Prassek, M. Rothenberg-Thurley, M. Sauerland, T. Herold, Hanna Janke, B. Ksienzyk, N. Konstandin, D. Goerlich, U. Krug, A. Faldum, W. Berdel, B. Wörmann, J. Braess, S. Schneider, M. Subklewe, S. Bohlander, W. Hiddemann, K. Spiekermann, K. Metzeler (2018)
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or olderHaematologica, 103
E. Lechman, B. Gentner, Stanley Ng, E. Schoof, P. Galen, J. Kennedy, S. Nucera, F. Ciceri, K. Kaufmann, N. Takayama, Stephanie Dobson, Aaron Trotman-Grant, Gabriela Krivdova, Janneke Elzinga, Amanda Mitchell, B. Nilsson, Karin Hermans, Kolja Eppert, René Marke, Ruth Isserlin, V. Voisin, Gary Bader, P. Zandstra, T. Golub, B. Ebert, Jun Lu, M. Minden, Jean Wang, L. Naldini, J. Dick (2016)
miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem CellsCancer Cell, 29
M. Sakaguchi, H. Yamaguchi, Marika Kuboyama, Y. Najima, K. Usuki, T. Ueki, I. Oh, S. Mori, E. Kawata, N. Uoshima, Yutaka Kobayashi, S. Kako, K. Tajika, Katsuhiro Shono, K. Kayamori, M. Hagihara, J. Kanda, H. Uchiyama, J. Kuroda, N. Uchida, Y. Kubota, S. Kimura, S. Kurosawa, Kenta Date, Nana Nakajima, A. Marumo, Ikuko Omori, Y. Fujiwara, K. Terada, Shunsuke Yui, S. Wakita, Kunihito Arai, T. Kitano, K. Kakihana, Y. Kanda, K. Ohashi, T. Fukuda, K. Inokuchi (2019)
Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemiaInternational Journal of Hematology, 110
Jay Patel, M. Gönen, M. Figueroa, H. Fernandez, Zhuoxin Sun, J. Racevskis, P. Vlierberghe, Igor Dolgalev, S. Thomas, Olga Aminova, K. Huberman, Janice Cheng, A. Viale, N. Socci, A. Heguy, A. Cherry, G. Vance, R. Higgins, R. Ketterling, R. Gallagher, M. Litzow, M. Brink, H. Lazarus, J. Rowe, S. Luger, A. Ferrando, E. Paietta, M. Tallman, A. Melnick, O. Abdel-Wahab, R. Levine (2012)
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.The New England journal of medicine, 366 12
T. Ley, C. Miller, L. Ding, Benjamin Raphael, A. Mungall, A. Robertson, K. Hoadley, T. Triche, P. Laird, J. Baty, L. Fulton, R. Fulton, S. Heath, Joelle Kalicki-Veizer, C. Kandoth, J. Klco, D. Koboldt, K. Kanchi, S. Kulkarni, T. Lamprecht, D. Larson, Ling Lin, Charles Lu, M. McLellan, Joshua McMichael, J. Payton, Heather Schmidt, D. Spencer, M. Tomasson, J. Wallis, L. Wartman, M. Watson, J. Welch, M. Wendl, Adrian Ally, M. Balasundaram, I. Birol, Y. Butterfield, Readman Chiu, Andy Chu, E. Chuah, Hye-Jung Chun, R. Corbett, Noreen Dhalla, R. Guin, A. He, Carrie Hirst, M. Hirst, R. Holt, Steven Jones, A. Karsan, Darlene Lee, H. Li, M. Marra, Michael Mayo, Richard Moore, K. Mungall, J. Parker, E. Pleasance, Patrick Plettner, J. Schein, D. Stoll, Lucas Swanson, Angela Tam, N. Thiessen, R. Varhol, N. Wye, Yongjun Zhao, S. Gabriel, G. Getz, C. Sougnez, L. Zou, Mark Leiserson, Fabio Vandin, Hsin-Ta Wu, F. Applebaum, S. Baylin, R. Akbani, B. Broom, Ken Chen, Thomas Motter, Khanh Nguyen, J. Weinstein, Nianziang Zhang, M. Ferguson, C. Adams, Aaron Black, Jay Bowen, J. Gastier-Foster, T. Grossman, T. Lichtenberg, L. Wise, Tanja Davidsen, John Demchok, K. Shaw, Margi Sheth, H. Sofia, Liming Yang, J. Downing, G. Eley (2013)
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.The New England journal of medicine, 368 22
E. Verovskaya, F. Calero-Nieto, D. Reynaud, S. Zhang, A. Hérault, Sietske Bakker, E. Pietras, A. Svendsen, Xiaonan Wang, S. Kinston, Theodore Ho, B. Göttgens, E. Passegué (2018)
Inflammatory Changes in the Bone Marrow Microenvironment Drive Both Niche and Blood System Remodeling during AgingExperimental Hematology
S. Daigle, S. Choe, L. Quek, C. Dinardo, A. Stein, E. Stein, A. Fathi, O. Frankfurt, A. Schuh, H. Kantarjian, V. Zhang, T. Winkler, P. Vyas, Bin Wu (2019)
High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and AzacitidineBlood
C. Roermund, E. Hettema, A. Kal, M. Berg, H. Tabak, R. Wanders (1998)
Peroxisomal β‐oxidation of polyunsaturated fatty acids in Saccharomyces cerevisiae: isocitrate dehydrogenase provides NADPH for reduction of double bonds at even positionsThe EMBO Journal, 17
R. Cairns, I. Papandreou, N. Denko (2006)
Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor MicroenvironmentMolecular Cancer Research, 4
W. Fiedler, S. Kayser, M. Kebenko, M. Janning, J. Krauter, M. Schittenhelm, K. Götze, D. Weber, G. Göhring, V. Teleanu, F. Thol, M. Heuser, K. Döhner, A. Ganser, H. Döhner, R. Schlenk (2015)
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutationsBritish Journal of Haematology, 169
Yu-Ting Chang, D. Hernandez, S. Alonso, Minling Gao, Meng Su, G. Ghiaur, M. Levis, Richard Jones (2019)
Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.Blood advances, 3 6
A. Khwaja, M. Bjorkholm, R. Gale, R. Levine, C. Jordan, G. Ehninger, C. Bloomfield, E. Estey, A. Burnett, J. Cornelissen, D. Scheinberg, D. Bouscary, D. Linch (2016)
Acute myeloid leukaemiaNature Reviews Disease Primers, 2
M. Burgess, E. Hwang, Ari Firestone, Tannie Huang, Jin Xu, J. Zuber, Natacha Bohin, Tiffany Wen, S. Kogan, K. Haigis, D. Sampath, S. Lowe, K. Shannon, Qing Li (2014)
Preclinical efficacy of MEK inhibition in Nras-mutant AML.Blood, 124 26
E. Bakker, M. Qattan, L. Mutti, C. Demonacos, M. Krstic-Demonacos (2016)
The role of microenvironment and immunity in drug response in leukemia.Biochimica et biophysica acta, 1863 3
M. Levis (2017)
Midostaurin approved for FLT3-mutated AML.Blood, 129 26
Catherine Smith, M. Levis, O. Frankfurt, J. Pagel, G. Roboz, R. Stone, E. Wang, P. Severson, B. West, M. Le, S. Kayser, B. Lam, H. Hsu, Chao Zhang, G. Bollag, A. Perl (2020)
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.Blood advances, 4 8
Andrew Matthews, A. Perl, S. Luger, A. Loren, S. Gill, D. Porter, D. Babushok, I. Maillard, M. Carroll, N. Frey, E. Hexner, Mary-Ellen Martin, Shannon McCurdy, E. Stadtmauer, V. Paralkar, Ximena Bruno, W. Hwang, David Margolis, K. Pratz (2022)
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaBlood Advances, 6
F. Stölzel, C. Steudel, U. Oelschlägel, B. Mohr, S. Koch, G. Ehninger, C. Thiede (2010)
Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cellsAnnals of Hematology, 89
Melat Gebru, Hong-Gang Wang (2020)
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemiaJournal of Hematology & Oncology, 13
A. Isidori, C. Cerchione, N. Daver, C. Dinardo, G. Garcia-Manero, M. Konopleva, E. Jabbour, F. Ravandi, T. Kadia, A. Burguera, A. Romano, F. Loscocco, G. Visani, G. Martinelli, H. Kantarjian, A. Curti (2021)
Immunotherapy in Acute Myeloid Leukemia: Where We StandFrontiers in Oncology, 11
M. Yilmaz, H. Kantarjian, N. Short, P. Reville, M. Konopleva, T. Kadia, C. Dinardo, G. Borthakur, N. Pemmaraju, A. Maiti, E. Jabbour, N. Jain, G. Issa, Koichi Takahashi, K. Sasaki, M. Ohanian, S. Pierce, G. Tang, S. Loghavi, K. Patel, Sa Wang, G. Garcia-Manero, M. Andreeff, F. Ravandi, N. Daver (2022)
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AMLBlood Cancer Journal, 12
N. Daver, R. Schlenk, N. Russell, M. Levis (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidenceLeukemia, 33
Ninib Baryawno, Dariusz Przybylski, Monika Kowalczyk, Y. Kfoury, N. Severe, K. Gustafsson, Konstantinos Kokkaliaris, F. Mercier, M. Tabaka, Matan Hofree, Danielle Dionne, Ani Papazian, Dongjun Lee, Orr Ashenberg, Ayshwarya Subramanian, E. Vaishnav, O. Rozenblatt-Rosen, A. Regev, D. Scadden (2019)
A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and LeukemiaCell, 177
Pamela Sung, M. Sugita, H. Koblish, A. Perl, M. Carroll (2019)
Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia.Blood advances, 3 7
R. Schlenk, P. Frech, D. Weber, P. Brossart, H. Horst, D. Kraemer, G. Held, M. Ringhoffer, A. Burchardt, G. Kobbe, K. Götze, D. Nachbaur, T. Fischer, M. Lübbert, H. Salih, H. Salwender, G. Wulf, E. Koller, M. Wattad, W. Fiedler, S. Kremers, H. Kirchen, B. Hertenstein, P. Paschka, V. Gaidzik, V. Teleanu, M. Heuser, F. Thol, K. Döhner, J. Krauter, A. Ganser, H. Döhner (2017)
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemiaLeukemia, 31
N. Chapuis, J. Tamburini, A. Green, C. Vignon, V. Bardet, Aymeric Neyret, M. Pannetier, L. Willems, Sophie Park, Alexandre Macone, S. Maira, N. Ifrah, F. Dreyfus, O. Hérault, C. Lacombe, P. Mayeux, D. Bouscary (2010)
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid LeukemiaClinical Cancer Research, 16
N. Jacque, A. Ronchetti, C. Larrue, G. Meunier, R. Birsen, L. Willems, E. Saland, J. Decroocq, T. Maciel, M. Lambert, Laury Poulain, Marie-Anne Hospital, P. Sujobert, Laure Joseph, N. Chapuis, C. Lacombe, I. Moura, S. Demo, J. Sarry, C. Récher, P. Mayeux, J. Tamburini, D. Bouscary (2015)
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.Blood, 126 11
M. Tallman, E. Wang, J. Altman, F. Appelbaum, V. Bhatt, D. Bixby, S. Coutre, M. Lima, A. Fathi, M. Fiorella, J. Foran, Aric Hall, Meagan Jacoby, J. Lancet, T. Leblanc, G. Mannis, G. Marcucci, Mike Martin, A. Mims, M. O'donnell, R. Olin, D. Peker, A. Perl, D. Pollyea, K. Pratz, T. Prebet, F. Ravandi, P. Shami, R. Stone, S. Strickland, M. Wieduwilt, K. Gregory, Lydia Hammond, Ndiya Ogba (2019)
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN, 17 6
Rongqing Pan, L. Hogdal, J. Benito, D. Bucci, Lina Han, G. Borthakur, J. Cortes, D. DeAngelo, Lakeisha Debose, H. Mu, H. Döhner, V. Gaidzik, I. Galinsky, L. Golfman, T. Haferlach, Karine Harutyunyan, Jianhua Hu, J. Leverson, G. Marcucci, M. Müschen, R. Newman, E. Park, P. Ruvolo, V. Ruvolo, J. Ryan, S. Schindela, P. Zweidler-McKay, R. Stone, H. Kantarjian, M. Andreeff, M. Konopleva, A. Letai (2014)
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.Cancer discovery, 4 3
T. Suda, K. Takubo, G. Semenza (2011)
Metabolic regulation of hematopoietic stem cells in the hypoxic niche.Cell stem cell, 9 4
M. Konopleva, C. Jordan (2011)
Leukemia stem cells and microenvironment: biology and therapeutic targeting.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 5
Steven Feins, Weimin Kong, E. Williams, M. Milone, J. Fraietta (2019)
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancerAmerican Journal of Hematology, 94
H. Döhner, E. Estey, D. Grimwade, S. Amadori, F. Appelbaum, T. Büchner, H. Dombret, B. Ebert, P. Fenaux, R. Larson, R. Levine, F. Lo‐Coco, T. Naoe, D. Niederwieser, G. Ossenkoppele, M. Sanz, J. Sierra, M. Tallman, H. Tien, A. Wei, B. Löwenberg, C. Bloomfield (2017)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Blood, 129 4
Francesca Hogan, Victoria Williams, S. Knapper (2020)
FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.Current cancer drug targets
Haijiao Zhang, S. Savage, Anna Schultz, D. Bottomly, Libbey White, E. Segerdell, B. Wilmot, S. McWeeney, C. Eide, T. Nechiporuk, A. Carlos, Rachel Henson, Chen-Jzong Lin, R. Searles, Hoang Ho, Y. Lam, R. Sweat, Courtney Follit, V. Jain, E. Lind, G. Borthakur, G. Garcia-Manero, F. Ravandi, H. Kantarjian, J. Cortes, R. Collins, D. Buelow, S. Baker, B. Druker, J. Tyner (2019)
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanismsNature Communications, 10
(2016)
Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivityOncotarget, 7
Songbai Liu, Haojie Dong, X. Bao, Q. Qiu, Hong-Zhi Li, Hongjie Shen, Z. Ding, Chao Wang, X. Chu, Jing-Qiu Yu, T. Tao, Zheng Li, Xiaowen Tang, Suning Chen, De-Pei Wu, Ling Li, S. Xue (2018)
Impact of FLT3-ITD length on prognosis of acute myeloid leukemiaHaematologica, 104
BA Jonas, DA Pollyea (2019)
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia, 33
R. Lindsley, B. Mar, E. Mazzola, Peter Grauman, S. Shareef, Steven Allen, A. Pigneux, M. Wetzler, Robert Stuart, H. Erba, Lloyd Damon, B. Powell, Neal Lindeman, D. Steensma, M. Wadleigh, D. DeAngelo, D. Neuberg, Richard Stone, Benjamin Ebert (2015)
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.Blood, 125 9
Courtney Jones, Brett Stevens, A. D’Alessandro, J. Reisz, Rachel Culp-Hill, T. Nemkov, Shanshan Pei, Nabilah Khan, Biniam Adane, Haobin Ye, Anna Krug, Dominik Reinhold, Clayton Smith, J. DeGregori, D. Pollyea, C. Jordan (2018)
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.Cancer cell, 34 5
S. Mccormick, M. McCormick, P. Grutkoski, Gregory Ducker, N. Banerji, R. Higgins, J. Mendiola, J. Reinartz (2010)
FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology.Archives of pathology & laboratory medicine, 134 8
Melat Gebru, J. Atkinson, Megan Young, Lijun Zhang, Zhenyuan Tang, Zhenqiu Liu, Pinyi Lu, Christopher Dower, Longgui Chen, C. Annageldiyev, Arati Sharma, Y. Kawasawa, Zhongming Zhao, B. Miller, D. Claxton, Hong-Gang Wang (2020)
Glucocorticoids enhance the anti-leukemic activity of FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.Blood
Lanlan Hui, Ye Chen (2015)
Tumor microenvironment: Sanctuary of the devil.Cancer letters, 368 1
J. Megías-Vericat, D. Martínez-Cuadrón, A. Solana-Altabella, J. Poveda, P. Montesinos (2022)
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid LeukemiaPharmaceutics, 14
K. Pratz, Takashi Sato, K. Murphy, A. Stine, T. Rajkhowa, M. Levis (2010)
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.Blood, 115 7
M. Warren, R. Luthra, C. Yin, F. Ravandi, Jordi Cortés, H. Kantarjian, L. Medeiros, Z. Zuo (2012)
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patientsModern Pathology, 25
Courtney Jones, Anagha Inguva, C. Jordan (2021)
Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors.Cell stem cell, 28 3
L. Shih, Chein‐Fuang Huang, Jin‐Hou Wu, Tung‐Liang Lin, P. Dunn, Po‐Nan Wang, M. Kuo, C. Lai, H. Hsu (2002)
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse.Blood, 100 7
M. Gregory, T. Nemkov, J. Reisz, Vadym Zaberezhnyy, K. Hansen, A. D’Alessandro, J. DeGregori (2017)
Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.Experimental hematology, 58
J. Molina, Yuting Sun, Marina Protopopova, S. Gera, Madhavi Bandi, C. Bristow, Timothy McAfoos, Pietro Morlacchi, J. Ackroyd, Ahmed-Noor Agip, G. Al-Atrash, J. Asara, Jennifer Bardenhagen, Caroline Carrillo, C. Carroll, Edward Chang, S. Ciurea, J. Cross, B. Czako, Angela Deem, Naval Daver, J. Groot, Jianwen Dong, Ningping Feng, G. Gao, J. Gay, M. Do, J. Greer, Virginia Giuliani, Jingchao Han, Lina Han, V. Henry, J. Hirst, Shan Huang, Yongying Jiang, Zhijun Kang, T. Khor, S. Konoplev, Yu-Hsi Lin, Gang Liu, A. Lodi, Timothy Lofton, Helen Ma, Mikhila Mahendra, Polina Matre, Robert Mullinax, M. Peoples, A. Petrocchi, J. Rodriguez-Canale, Riccardo Serreli, T. Shi, Melinda Smith, Y. Tabe, Jay Theroff, S. Tiziani, Quanyu Xu, Qi Zhang, Florian Muller, R. DePinho, C. Toniatti, G. Draetta, T. Heffernan, M. Konopleva, Philip Jones, M. Francesco, J. Marszalek (2018)
An inhibitor of oxidative phosphorylation exploits cancer vulnerabilityNature Medicine, 24
N. Podoltsev, M. Stahl, A. Zeidan, S. Gore (2017)
Selecting initial treatment of acute myeloid leukaemia in older adults.Blood reviews, 31 2
Catherine Smith, Qi Wang, C. Chin, S. Salerno, L. Damon, M. Levis, A. Perl, K. Travers, Susana Wang, Jeremy Hunt, P. Zarrinkar, E. Schadt, A. Kasarskis, J. Kuriyan, N. Shah (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature, 485
P. Paschka, R. Schlenk, V. Gaidzik, Marianne Habdank, J. Krönke, L. Bullinger, D. Späth, S. Kayser, M. Zucknick, K. Götze, H. Horst, U. Germing, H. Döhner, K. Döhner (2010)
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 22
Manar Shafat, Bruno Gnaneswaran, K. Bowles, S. Rushworth (2017)
The bone marrow microenvironment - Home of the leukemic blasts.Blood reviews, 31 5
(2016)
The 2016 revision to the WorldHealthOrganizationclassificationofmyeloidneoplasms and acute leukemia
S. Choe, Hongfang Wang, C. Dinardo, E. Stein, S. Botton, G. Roboz, J. Altman, A. Mims, J. Watts, D. Pollyea, A. Fathi, M. Tallman, H. Kantarjian, R. Stone, L. Quek, Z. Konteatis, L. Dang, Brandon Nicolay, Parham Nejad, Guowen Liu, V. Zhang, Hua Liu, M. Goldwasser, Wei Liu, K. Marks, C. Bowden, S. Biller, E. Attar, Bin Wu (2020)
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.Blood advances, 4 9
S. Méndez-Ferrer, D. Bonnet, D. Steensma, R. Hasserjian, I. Ghobrial, J. Gribben, Michael Andreeff , D. Krause (2020)
Bone marrow niches in haematological malignanciesNature Reviews Cancer, 20
Maria Galkin, B. Jonas (2019)
Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapyCore Evidence, 14
M. Heuser, M. Cruz, Ramya Goparaju, Anuhar Chaturvedi (2015)
Enigmas of IDH mutations in hematology/oncology.Experimental hematology, 43 8
F. Vasconcelos, P. Souza, Thaís Hancio, F. Faria, R. Maia (2021)
UPDATE ON DRUG TRANSPORTER PROTEINS IN ACUTE MYELOID LEUKEMIA: PATHOLOGICAL IMPLICATION AND CLINICAL SETTING.Critical reviews in oncology/hematology
P. Sujobert, V. Bardet, P. Cornillet‐Lefèbvre, J. Hayflick, N. Prié, F. Verdier, B. Vanhaesebroeck, O. Muller, F. Pesce, N. Ifrah, M. Hunault-Berger, C. Berthou, B. Villemagne, E. Jourdan, B. Audhuy, E. Solary, B. Witz, J. Harousseau, C. Himberlin, T. Lamy, B. Lioure, J. Cahn, F. Dreyfus, P. Mayeux, C. Lacombe, D. Bouscary (2005)
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.Blood, 106 3
Celeste Holz-Schietinger, Douglas Matje, N. Reich (2012)
Mutations in DNA Methyltransferase (DNMT3A) Observed in Acute Myeloid Leukemia Patients Disrupt Processive MethylationThe Journal of Biological Chemistry, 287
Jennifer Campbell-Hicks (2015)
Prime timeNature, 526
B. Falini, C. Mecucci, E. Tiacci, M. Alcalay, R. Rosati, L. Pasqualucci, R. Starza, D. Diverio, E. Colombo, A. Santucci, B. Bigerna, R. Pacini, A. Pucciarini, A. Liso, M. Vignetti, P. Fazi, Natalia Meani, V. Pettirossi, G. Saglio, F. Mandelli, F. Lo‐Coco, P. Pelicci, M. Martelli (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.The New England journal of medicine, 352 3
U. Bacher, C. Haferlach, W. Kern, T. Haferlach, S. Schnittger (2008)
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.Blood, 111 5
Peter Bross, J. Beitz, Gang Chen, X. Chen, E. Duffy, L. Kieffer, Sandip Roy, R. Sridhara, Atiqur Rahman, G. Williams, R. Pazdur (2001)
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 6
H. Hunter, M. Pallis, C. Seedhouse, Martin Grundy, C. Gray, N. Russell (2004)
The expression of P‐glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitorsBritish Journal of Haematology, 127
T. Matsunaga, N. Takemoto, Tsutomu Sato, R. Takimoto, I. Tanaka, A. Fujimi, T. Akiyama, H. Kuroda, Y. Kawano, M. Kobune, J. Kato, Y. Hirayama, S. Sakamaki, K. Kohda, K. Miyake, Y. Niitsu (2003)
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemiaNature Medicine, 9
Diana Hanekamp, J. Cloos, G. Schuurhuis (2017)
Leukemic stem cells: identification and clinical applicationInternational Journal of Hematology, 105
(2020)
Study Offers Insights on Prognostic Significance of IDH Mutations Across Age Groups in AML.The oncologist
D. Grimwade, S. Freeman (2014)
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?Blood, 124 23
Zachary Reitman, Hai Yan (2010)
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.Journal of the National Cancer Institute, 102 13
Z. Zeng, Yue-xi Shi, I. Samudio, Rui-yu Wang, Xiaoyang Ling, O. Frolova, M. Levis, J. Rubin, R. Negrin, E. Estey, S. Konoplev, M. Andreeff, M. Konopleva (2009)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.Blood, 113 24
Kuangguo Zhou, Li-jun Jiang, Z. Shang, Jue Wang, Liang Huang, Jian-Feng Zhou (2012)
Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysisLeukemia & Lymphoma, 53
M. Wattad, D. Weber, K. Döhner, J. Krauter, V. Gaidzik, P. Paschka, M. Heuser, F. Thol, T. Kindler, M. Lübbert, H. Salih, A. Kündgen, H. Horst, P. Brossart, K. Götze, D. Nachbaur, C.-H. Köhne, M. Ringhoffer, G. Wulf, G. Held, H. Salwender, A. Benner, A. Ganser, H. Döhner, R. Schlenk (2017)
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failureLeukemia, 31
E. Jen, Xin Wang, Meng Li, Hongshan Li, Shwu-Luan Lee, Nina Ni, D. Przepiorka, Jonathon Vallejo, Ruby Leong, Lian Ma, Brenda Gehrke, Sherita McLamore, M. Theoret, R. Claro (2022)
FDA Approval Summary: Oral Azacitidine For Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research
Polina Matre, J. Velez, R. Jacamo, Y. Qi, Xiaoping Su, Tianyu Cai, Steven Chan, A. Lodi, Shannon Sweeney, Helen Ma, R. Davis, Natalia Baran, T. Haferlach, X. Su, E. Flores, D. Gonzalez, S. Konoplev, I. Samudio, C. Dinardo, R. Majeti, A. Schimmer, Weiqun Li, Taotao Wang, S. Tiziani, M. Konopleva (2016)
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypesOncotarget, 7
C. Schmid, M. Labopin, G. Socié, É. Daguindau, L. Volin, A. Huynh, J. Bourhis, N. Milpied, J. Cornelissen, P. Chevallier, J. Maertens, P. Jindra, D. Blaise, S. Lenhoff, N. Ifrah, F. Baron, F. Ciceri, C. Gorin, B. Savani, S. Giebel, E. Polge, J. Esteve, A. Nagler, M. Mohty (2015)
Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.Blood, 126 17
G. Montalban-Bravo, C. Dinardo (2018)
The role of IDH mutations in acute myeloid leukemia.Future oncology, 14 10
Servais Sophie, Beguin Yves, Baron Frédéric (2022)
Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia.Stem cells translational medicine
E. Pulte, K. Norsworthy, Yaping Wang, Qing Xu, Hisham Qosa, R. Gudi, D. Przepiorka, W. Fu, O. Okusanya, Kirsten Goldberg, R. Claro, A. Farrell, R. Pazdur (2021)
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 MutationClinical Cancer Research, 27
Catherine Smith, Kimberly Lin, A. Stecula, A. Sali, N. Shah (2015)
FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 InhibitorsLeukemia, 29
(2019)
PollyeaDA.Howweuse venetoclaxwith hypomethylating agents for the treatment of newly diagnosed patients with acutemyeloid leukemia. Leukemia
Graeme Sullivan, Lyndsey Flanagan, D. Rodrigues, T. Chonghaile (2022)
The path to venetoclax resistance is paved with mutations, metabolism, and moreScience Translational Medicine, 14
Stephan Bartholomae, B. Gruhn, K. Debatin, M. Zimmermann, U. Creutzig, D. Reinhardt, D. Steinbach (2016)
Coexpression of Multiple ABC‐Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid LeukemiaPediatric Blood & Cancer, 63
G. Tamamyan, T. Kadia, F. Ravandi, G. Borthakur, J. Cortes, E. Jabbour, N. Daver, M. Ohanian, H. Kantarjian, M. Konopleva (2017)
Frontline treatment of acute myeloid leukemia in adults.Critical reviews in oncology/hematology, 110
S Pei, DA Pollyea, A Gustafson (2020)
Monocytic subclones confer resistance to venetoclax‐based therapy in patients with acute myeloid leukemia, 10
N. Daver, A. Maiti, T. Kadia, P. Vyas, R. Majeti, A. Wei, G. Garcia-Manero, C. Craddock, D. Sallman, H. Kantarjian (2022)
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future DirectionsCancer Discovery, 12
R. Schlenk, S. Kayser (2018)
Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 212
C. Man, T. Fung, C. Ho, H. Han, H. Chow, Alvin Ma, W. Choi, S. Lok, Alice Cheung, C. Eaves, Y. Kwong, A. Leung (2012)
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.Blood, 119 22
M. Figueroa, O. Abdel-Wahab, Chao Lu, P. Ward, Jay Patel, A. Shih, Yushan Li, N. Bhagwat, A. Vasanthakumar, H. Fernandez, M. Tallman, Zhuoxin Sun, K. Wolniak, J. Peeters, Wei Liu, S. Choe, V. Fantin, E. Paietta, B. Löwenberg, J. Licht, L. Godley, R. Delwel, P. Valk, C. Thompson, R. Levine, A. Melnick (2010)
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.Cancer cell, 18 6
J. Styczyński, G. Tridello, L. Koster, S. Iacobelli, A. Biezen, S. Werf, M. Mikulska, L. Gil, C. Cordonnier, P. Ljungman, D. Averbuch, S. Cesaro, R. Cámara, H. Baldomero, P. Bader, G. Basak, C. Bonini, R. Duarte, C. Dufour, J. Kuball, A. Lankester, S. Montoto, A. Nagler, J. Snowden, N. Kröger, M. Mohty, A. Gratwohl (2019)
Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factorsBone Marrow Transplantation, 55
H. Döhner, K. Pratz, C. Dinardo, B. Jonas, V. Pullarkat, M. Thirman, C. Récher, A. Schuh, S. Babu, Monique Dail, G. Ku, Yan Sun, J. Potluri, B. Chyla, D. Pollyea (2022)
ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and AzacitidineBlood
A. Wei, S. Strickland, Jingzhou Hou, W. Fiedler, T. Lin, R. Walter, A. Enjeti, I. Tiong, M. Savona, Sangmin Lee, B. Chyla, R. Popovic, A. Salem, S. Agarwal, T. Xu, Kaffa Fakouhi, R. Humerickhouse, W. Hong, J. Hayslip, G. Roboz (2019)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II StudyJournal of Clinical Oncology, 37
M. Gallazzi, Maghalie Ucciero, D. Faraci, A. Mahmoud, Wael Essa, G. Gaidano, S. Mouhssine, E. Crisà (2022)
New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic SyndromesInternational Journal of Molecular Sciences, 23
Ying-hua Wang, William Israelsen, Dongjun Lee, V. Yu, N. Jeanson, C. Clish, L. Cantley, M. Heiden, D. Scadden (2014)
Cell-State-Specific Metabolic Dependency in Hematopoiesis and LeukemogenesisCell, 158
Sophie Park, N. Chapuis, F. Saint-marcoux, C. Récher, T. Prebet, P. Chevallier, J. Cahn, T. Leguay, P. Bories, F. Witz, T. Lamy, P. Mayeux, C. Lacombe, C. Demur, J. Tamburini, A. Merlat, R. Delépine, N. Vey, F. Dreyfus, M. Béné, N. Ifrah, D. Bouscary (2013)
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseLeukemia, 27
M. Larrosa-Garcia, M. Baer (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future DirectionsMolecular Cancer Therapeutics, 16
PARK and GREGORY
Sascha Haubner, F. Perna, T. Köhnke, C. Schmidt, Samuel Berman, C. Augsberger, Frauke Schnorfeil, Christina Krupka, F. Lichtenegger, X. Liu, Paul Kerbs, S. Schneider, K. Metzeler, K. Spiekermann, W. Hiddemann, P. Greif, T. Herold, M. Sadelain, M. Subklewe (2018)
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AMLLeukemia, 33
Derek Stirewalt, K. Kopecky, S. Meshinchi, Julia Engel, E. Pogosova-Agadjanyan, Jeremy Linsley, M. Slovak, C. Willman, J. Radich (2006)
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.Blood, 107 9
F. Ong, Kunhwa Kim, M. Konopleva (2022)
Venetoclax resistance: mechanistic insights and future strategiesCancer Drug Resistance, 5
Y. Alvarado, H. Kantarjian, R. Luthra, F. Ravandi, G. Borthakur, G. Garcia-Manero, M. Konopleva, Z. Estrov, M. Andreeff, J. Cortes (2014)
Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutationsCancer, 120
J. Loke, Richard Buka, C. Craddock (2021)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?Frontiers in Immunology, 12
D. Pollyea, Brett Stevens, Courtney Jones, Amanda Winters, Shanshan Pei, Mohammad Minhajuddin, A. D’Alessandro, Rachel Culp-Hill, K. Riemondy, A. Gillen, J. Hesselberth, Diana Abbott, Derek Schatz, J. Gutman, E. Purev, Clayton Smith, C. Jordan (2018)
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemiaNature Medicine, 24
Banban Li, Rui-ping Jia, Wei Li, Ying Zhou, D. Guo, Q. Teng, S. Du, Mingying Li, Wei Li, Tao Sun, D. Ma, Min Ji, C. Ji (2021)
PAK1 Mediates Bone Marrow Stromal Cell-Induced Drug Resistance in Acute Myeloid Leukemia via ERK1/2 Signaling PathwayFrontiers in Cell and Developmental Biology, 9
P. Simmons, B. Masinovsky, B. Longenecker, R. Berenson, B. Torok-Storb, W. Gallatin (1992)
Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells.Blood, 80 2
S. Bertoli, M. Picard, E. Bérard, E. Griessinger, C. Larrue, P. Mouchel, F. Vergez, S. Tavitian, E. Yon, J. Ruiz, É. Delabesse, I. Luquet, L. Linares, E. Saland, M. Carroll, G. Danet-Desnoyers, A. Sarry, F. Huguet, J. Sarry, C. Récher (2018)
Dexamethasone in hyperleukocytic acute myeloid leukemiaHaematologica, 103
Feng Wang, Kiyomi Morita, C. Dinardo, Ken Furudate, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan, K. Patel, K. Macbeth, Bin Wu, Guowen Liu, M. Frattini, J. Matthews, L. Little, C. Gumbs, Xingzhi Song, Jianhua Zhang, Erika Thompson, T. Kadia, G. Garcia-Manero, E. Jabbour, F. Ravandi, K. Bhalla, M. Konopleva, H. Kantarjian, P. Futreal, Koichi Takahashi (2020)
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemiaNature Communications, 12
Ami Patel, A. Pomicter, D. Yan, A. Eiring, Orlando Antelope, J. Schumacher, T. Kelley, S. Tantravahi, T. Kovacsovics, P. Shami, T. O'hare, M. Deininger (2020)
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanismsLeukemia, 34
Wen-Lian Chen, Jinghan Wang, A. Zhao, Xin Xu, Yihuang Wang, Tian-lu Chen, Junmin Li, J. Mi, Yong-mei Zhu, Yuan-fang Liu, Yue-Ying Wang, Jie Jin, He Huang, De-Pei Wu, Yan Li, Xiao-jing Yan, Jin-Song Yan, Jian-yong Li, Shuaifang Wang, Xiao-jun Huang, Bing-Shun Wang, Zhu Chen, Saijuan Chen, Wei Jia (2014)
A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value.Blood, 124 10
O. Piloto, Melissa Wright, P. Brown, Kyu‐Tae Kim, M. Levis, D. Small (2006)
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.Blood, 109 4
R. Guardia, B. López‐Millán, J. Lavoie, C. Bueno, J. Castaño, M. Gómez-Casares, S. Vives, L. Palomo, M. Juan, Julio Delgado, M. Blanco, J. Nomdedéu, A. Chaparro, J. Fuster, E. Anguita, M. Rosu-Myles, P. Menéndez (2017)
Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment OutcomesStem Cell Reports, 8
I. Moors, K. Vandepoele, J. Philippé, D. Deeren, D. Selleslag, D. Breems, N. Straetmans, T. Kerre, B. Denys (2019)
Clinical implications of measurable residual disease in AML: Review of current evidence.Critical reviews in oncology/hematology, 133
C. López-Otín, M. Blasco, L. Partridge, M. Serrano, G. Kroemer (2013)
The Hallmarks of AgingCell, 153
Anne Wilson, A. Trumpp (2006)
Bone-marrow haematopoietic-stem-cell nichesNature Reviews Immunology, 6
C. Röllig, G. Ehninger (2015)
How I treat hyperleukocytosis in acute myeloid leukemia.Blood, 125 21
(2014)
Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia
D. Linch, R. Hills, A. Burnett, A. Khwaja, R. Gale (2014)
Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.Blood, 124 2
B. Shaffer, J. Gillet, C. Patel, M. Baer, S. Bates, M. Gottesman (2012)
Drug resistance: still a daunting challenge to the successful treatment of AML.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 15 1-2
Jochen Vasold, M. Wagner, Heidrun Drolle, Christian Deniffel, Alexander Kütt, R. Oostendorp, Silvia Sironi, C. Rieger, M. Fiegl (2015)
The bone marrow microenvironment is a critical player in the NK cell response against acute myeloid leukaemia in vitro.Leukemia research, 39 2
J. Cornelissen, A. Gratwohl, R. Schlenk, J. Sierra, M. Bornhäuser, G. Juliusson, Z. Ráčil, J. Rowe, N. Russell, M. Mohty, B. Löwenberg, G. Socié, D. Niederwieser, G. Ossenkoppele (2012)
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approachNature Reviews Clinical Oncology, 9
D. Pollyea, K. Pratz, A. Wei, V. Pullarkat, B. Jonas, C. Récher, S. Babu, A. Schuh, Monique Dail, Yan Sun, J. Potluri, B. Chyla, C. Dinardo (2022)
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and AzacitidineClinical Cancer Research, 28
K. Pratz (2018)
Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)Blood
F. Watt, B. Hogan (2000)
Out of Eden: stem cells and their niches.Science, 287 5457
M. Gregory, T. Nemkov, Hae‐Joon Park, Vadym Zaberezhnyy, S. Gehrke, Biniam Adane, C. Jordan, K. Hansen, A. D’Alessandro, J. DeGregori (2018)
Targeting Glutamine Metabolism and Redox State for Leukemia TherapyClinical Cancer Research, 25
(2020)
Fatty acid metabolism underliesvenetoclaxresistanceinacutemyeloidleukemiastem cells
D. Forte, M. García-Fernández, A. Sánchez-Aguilera, V. Stavropoulou, C. Fielding, D. Martín-Pérez, J. López, Ana Costa, L. Tronci, Efterpi Nikitopoulou, Michael Barber, P. Gallipoli, Ludovica Marando, Carlos Castillejo, A. Tzankov, S. Dietmann, M. Cavo, L. Catani, A. Curti, J. Vázquez, C. Frezza, B. Huntly, J. Schwaller, S. Méndez-Ferrer (2020)
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from ChemotherapyCell Metabolism, 32
K. Norsworthy, Kunthel By, Sriram Subramaniam, L. Zhuang, P. Valle, D. Przepiorka, Y. Shen, Christopher Sheth, Chao Liu, Ruby Leong, Kirsten Goldberg, A. Farrell, R. Pazdur (2019)
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid LeukemiaClinical Cancer Research, 25
Kun Yao, Hua Liu, Shui Yu, Haohao Zhu, Jie Pan (2022)
Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.Cancer letters
N. Daver, M. Konopleva, A. Maiti, T. Kadia, C. Dinardo, S. Loghavi, N. Pemmaraju, E. Jabbour, G. Montalban-Bravo, G. Tang, K. Sasaki, G. Borthakur, M. Yilmaz, J. Alvarez, Michelle Golez, S. Pierce, G. Gonzalez, J. Ning, H. Abbas, F. Ravandi, G. Garcia-Manero, H. Kantarjian (2021)
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AMLBlood
Kiyomi Morita, Kiyomi Morita, Feng Wang, Katharina Jahn, Katharina Jahn, T. Hu, Tomoyuki Tanaka, Yuya Sasaki, Jack Kuipers, Jack Kuipers, S. Loghavi, Sa Wang, Yuanqing Yan, Ken Furudate, Ken Furudate, J. Matthews, L. Little, C. Gumbs, Jianhua Zhang, Xingzhi Song, Erika Thompson, K. Patel, C. Bueso-Ramos, C. Dinardo, F. Ravandi, E. Jabbour, M. Andreeff, J. Cortes, K. Bhalla, G. Garcia-Manero, H. Kantarjian, M. Konopleva, Daisuke Nakada, N. Navin, N. Beerenwinkel, N. Beerenwinkel, P. Futreal, Koichi Takahashi (2020)
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsNature Communications, 11
A. Bazinet, S. Assouline (2021)
A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’Expert Review of Hematology, 14
C. Dinardo, A. Schuh, E. Stein, P. Montesinos, A. Wei, S. Botton, A. Zeidan, A. Fathi, H. Kantarjian, J. Bennett, M. Frattini, P. Martín-Regueira, F. Lersch, J. Gong, Maroof Hasan, P. Vyas, H. Döhner (2021)
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.The Lancet. Oncology
C. Dinardo, K. Pratz, V. Pullarkat, B. Jonas, M. Arellano, P. Becker, O. Frankfurt, M. Konopleva, A. Wei, H. Kantarjian, T. Xu, W. Hong, B. Chyla, J. Potluri, D. Pollyea, A. Letai (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.Blood, 133 1
Xiaoyan Liu, Y. Gong (2019)
Isocitrate dehydrogenase inhibitors in acute myeloid leukemiaBiomarker Research, 7
R. Stone, S. Mandrekar, B. Sanford, K. Laumann, S. Geyer, C. Bloomfield, K. Döhner, C. Thiede, G. Marcucci, F. Coco, R. Klisovic, A. Wei, J. Sierra, M. Sanz, J. Brandwein, T. Witte, D. Niederwieser, F. Appelbaum, B. Medeiros, M. Tallman, J. Krauter, R. Schlenk, A. Ganser, H. Serve, G. Ehninger, S. Amadori, H. Döhner, R. Larson (2017)
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 MutationsBlood, 130
E. Papaemmanuil, M. Gerstung, L. Bullinger, V. Gaidzik, P. Paschka, Nicola Roberts, N. Potter, M. Heuser, F. Thol, N. Bolli, G. Gundem, P. Loo, I. Martincorena, P. Ganly, L. Mudie, Stuart Mclaren, S. O'meara, K. Raine, David Jones, J. Teague, A. Butler, M. Greaves, A. Ganser, K. Döhner, R. Schlenk, H. Döhner, P. Campbell (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia.The New England journal of medicine, 374 23
T. Şimşek, Fatih Kocabaş, Junke Zheng, R. Deberardinis, A. Mahmoud, E. Olson, J. Schneider, C. Zhang, Hesham Sadek (2010)
The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche.Cell stem cell, 7 3
Hanna Wiktorin, Ebru Aydın, K. Christenson, Nuttida Issdisai, F. Thorén, K. Hellstrand, A. Martner (2021)
Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenanceOncoimmunology, 10
C. McMahon, Timothy Ferng, J. Canaani, E. Wang, J. Morrissette, D. Eastburn, M. Pellegrino, Robert Durruthy-Durruthy, C. Watt, S. Asthana, E. Lasater, R. DeFilippis, C. Peretz, Lisa McGary, Safoora Deihimi, A. Logan, S. Luger, N. Shah, M. Carroll, Catherine Smith, A. Perl (2019)
Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.Cancer discovery
S. Brunet, M. Labopin, J. Esteve, J. Cornelissen, G. Socié, A. Iori, L. Verdonck, L. Volin, A. Gratwohl, J. Sierra, M. Mohty, V. Rocha (2012)
Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 7
Kaimin Hu, Yanjun Gu, L. Lou, Lizhen Liu, Yong-xian Hu, Binsheng Wang, Yi Luo, Jimin Shi, Xiaohong Yu, He Huang (2015)
Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathwayJournal of Hematology & Oncology, 8
Xin He, Zijie Feng, Jian Ma, Sunbin Ling, Yan Cao, Buddha Gurung, Yuan Wu, Bryson Katona, Kienan O'dwyer, D. Siegel, C. June, X. Hua (2020)
Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia.Blood
H. Kiyoi, N. Kawashima, Y. Ishikawa (2019)
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor developmentCancer Science, 111
Y. Guan, B. Gerhard, D. Hogge (2003)
Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML).Blood, 101 8
P. Ward, Jay Patel, David Wise, O. Abdel-Wahab, Bryson Bennett, H. Coller, J. Cross, V. Fantin, C. Hedvat, A. Perl, J. Rabinowitz, M. Carroll, Shinsan Su, K. Sharp, R. Levine, C. Thompson (2010)
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Cancer cell, 17 3
PD Kottaridis, RE Gale, ME Frew (2001)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials, 98
M. Levis, A. Perl (2020)
Gilteritinib: potent targeting of FLT3 mutations in AML.Blood advances, 4 6
P. Kamga, Giulio Bassi, A. Cassaro, M. Midolo, M. Trapani, A. Gatti, Roberta Carusone, Federica Resci, O. Perbellini, M. Gottardi, M. Bonifacio, A. Kamdje, A. Ambrosetti, M. Krampera (2016)
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemiaOncotarget, 7
A. Rambaldi, M. Torcia, S. Bettoni, E. Vannier, T. Barbui, Alan, Shaw, C. Dinarello, Federico Cozzolino (1991)
Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells.Blood, 78 12
J. Lancet, G. Uy, J. Cortes, L. Newell, T. Lin, E. Ritchie, R. Stuart, S. Strickland, D. Hogge, S. Solomon, R. Stone, D. Bixby, J. Kolitz, G. Schiller, M. Wieduwilt, D. Ryan, A. Hoering, Kamalika Banerjee, M. Chiarella, A. Louie, B. Medeiros (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJournal of Clinical Oncology, 36
N. Fukushima, Y. Minami, Seiji Kakiuchi, Y. Kuwatsuka, F. Hayakawa, C. Jamieson, H. Kiyoi, T. Naoe (2016)
Small‐molecule Hedgehog inhibitor attenuates the leukemia‐initiation potential of acute myeloid leukemia cellsCancer Science, 107
E. Traer, Jacqueline Martinez, Nathalie Javidi-Sharifi, A. Agarwal, J. Dunlap, I. English, T. Kovacsovics, J. Tyner, M. Wong, B. Druker (2016)
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.Cancer research, 76 22
M. Heuser, S. Freeman, G. Ossenkoppele, F. Buccisano, C. Hourigan, L. Ngai, J. Tettero, C. Bachas, C. Baer, M. Béné, V. Bücklein, A. Czyż, B. Denys, R. Dillon, M. Feuring‐Buske, M. Guzman, T. Haferlach, Lina Han, J. Herzig, J. Jorgensen, W. Kern, M. Konopleva, F. Lacombe, M. Libura, Agata Majchrzak, L. Maurillo, Y. Ofran, J. Philippé, A. Plesa, C. Preudhomme, F. Ravandi, C. Roumier, M. Subklewe, F. Thol, A. Loosdrecht, B. Reijden, A. Venditti, A. Wierzbowska, P. Valk, B. Wood, R. Walter, C. Thiede, K. Döhner, G. Roboz, J. Cloos (2021)
2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.Blood
J. Vadakekolathu, M. Minden, T. Hood, S. Church, S. Reeder, H. Altmann, A. Sullivan, Elena Viboch, Tasleema Patel, N. Ibrahimova, S. Warren, A. Arruda, Yan Liang, Thomas Smith, G. Foulds, M. Bailey, J. Gowen-MacDonald, J. Muth, Marc Schmitz, Marc Schmitz, A. Cesano, A. Pockley, P. Valk, B. Löwenberg, M. Bornhäuser, S. Tasian, M. Rettig, J. Davidson-Moncada, J. Dipersio, S. Rutella (2019)
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemiaScience Translational Medicine, 12
Adam Ivey, R. Hills, M. Simpson, J. Jovanovic, A. Gilkes, A. Grech, Yashma Patel, N. Bhudia, H. Farah, J. Mason, Kerry Wall, S. Akiki, M. Griffiths, E. Solomon, F. McCaughan, D. Linch, R. Gale, P. Vyas, S. Freeman, N. Russell, A. Burnett, D. Grimwade (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML.The New England journal of medicine, 374 5
N. Brooks, R. Dewalt, S. Boulet, Z. Lu, L. Kays, Rachel Cavitt, S. Gomez, J. Strelow, P. Milligan, K. Roth, R. Bauer, S. Antonysamy, P. Hahn, Z. Rankovic, D. Mccann, G. Mo, R. Tiu, P. BurkholderTimothy, S. Geeganage, R. Gilmour (2019)
Abstract LB-274: Identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1)Experimental and Molecular Therapeutics
C. Franceschi, M. Bonafè, S. Valensin, F. Olivieri, M. Luca, E. Ottaviani, G. Benedictis (2000)
Inflamm‐aging: An Evolutionary Perspective on ImmunosenescenceAnnals of the New York Academy of Sciences, 908
S. Joshi, T. Nechiporuk, D. Bottomly, P. Piehowski, J. Reisz, Janét Pittsenbarger, A. Kaempf, Sara Gosline, Yi-Ting Wang, J. Hansen, M. Gritsenko, Chelsea Hutchinson, K. Weitz, J. Moon, F. Cendali, T. Fillmore, Chia-Feng Tsai, A. Schepmoes, Tujin Shi, O. Arshad, J. Mcdermott, O. Babur, Kevin Watanabe-Smith, E. Demir, A. D’Alessandro, Tao Liu, C. Tognon, J. Tyner, S. McWeeney, K. Rodland, B. Druker, E. Traer (2021)
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.Cancer cell
C. McMahon, J. Canaani, B. Rea, R. Sargent, J. Morrissette, David Lieberman, C. Watt, Gregory Schwartz, R. Faryabi, Timothy Ferng, N. Shah, Catherine Smith, M. Carroll, A. Perl (2017)
Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid LeukemiaBlood, 130
J. Cortes, M. Tallman, G. Schiller, D. Trone, G. Gammon, S. Goldberg, A. Perl, J. Marie, G. Martinelli, H. Kantarjian, M. Levis (2018)
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.Blood, 132 6
C. Ustun, H. Lazarus, D. Weisdorf (2013)
To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first centuryBone Marrow Transplantation, 48
E. Sison, P. Brown (2011)
The bone marrow microenvironment and leukemia: biology and therapeutic targetingExpert Review of Hematology, 4
F. Giles, H. Kantarjian, S. Kornblau, D. Thomas, G. Garcia-Manero, T. Waddelow, C. David, A. Phan, D. Colburn, A. Rashid, E. Estey (2001)
Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantationCancer, 92
M. Luskin, Ju-Whei Lee, H. Fernandez, O. Abdel-Wahab, J. Bennett, R. Ketterling, H. Lazarus, R. Levine, M. Litzow, E. Paietta, Jay Patel, J. Racevskis, J. Rowe, M. Tallman, Zhuoxin Sun, S. Luger (2016)
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.Blood, 127 12
Yeuan Lee, Y. Tan, C. Oon (2018)
Molecular targeted therapy: Treating cancer with specificityEuropean Journal of Pharmacology, 834
M. Levis (2017)
Blood Spotlight Midostaurin approved for FLT 3-mutated AML
Gert Ossenkoppele (2018)
Acute myeloid leukemiaHemaSphere, 2
Hawk Kim, Je-Hwan Lee, Seong-jun Choi, Woo-kun Kim, Jung-shin Lee, K. Lee (2004)
Analysis of fatal intracranial hemorrhage in 792 acute leukemia patients.Haematologica, 89 5
B. Carter, P. Mak, Ye Chen, D. Mak, H. Mu, R. Jacamo, V. Ruvolo, S. Arold, J. Ladbury, J. Burks, S. Kornblau, M. Andreeff (2016)
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling networkOncotarget, 7
M. Amatangelo, L. Quek, A. Shih, E. Stein, M. Roshal, M. David, B. Marteyn, N. Farnoud, S. Botton, O. Bernard, Bin Wu, K. Yen, M. Tallman, E. Papaemmanuil, V. Penard-Lacronique, A. Thakurta, P. Vyas, R. Levine (2017)
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Blood, 130 6
N. Mcgranahan, C. Swanton (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the FutureCell, 168
T. Grafone, M. Palmisano, Chiara Nicci, S. Storti (2012)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentOncology Reviews, 6
E. Traer, Jacqueline Martinez, Nathalie Javidi-Sharifi, A. Agarwal, Jennifer, Dunlap, I. English, T. Kovacsovics, J. Tyner, M. Wong, B. Druker (2017)
FGF 2 from marrow microenvironment promotes resistance to FLT 3 inhibitors in acute myeloid leukemia
N. Daver, A. Perl, J. Maly, M. Levis, E. Ritchie, M. Litzow, J. Mccloskey, Catherine Smith, G. Schiller, T. Bradley, R. Tiu, K. Naqvi, Monique Dail, Deanna Brackman, S. Siddani, Jing Wang, Brenda Chyla, Paula Lee, J. Altman (2022)
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid LeukemiaJournal of Clinical Oncology, 40
J. Cortes, S. Khaled, G. Martinelli, A. Perl, S. Ganguly, N. Russell, A. Krämer, H. Dombret, D. Hogge, B. Jonas, A. Leung, P. Mehta, P. Montesinos, M. Radsak, S. Sica, M. Arunachalam, M. Holmes, Ken Kobayashi, R. Namuyinga, Nanxiang Ge, A. Yver, Yufen Zhang, M. Levis (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.The Lancet. Oncology
Pablo Garcia, J. Langowski, Yingyun Wang, Min Chen, Joseph Castillo, C. Fanton, Marjorie Ison, T. Zavorotinskaya, Yumin Dai, Jing Lu, Xiaohong Niu, Stephen Basham, J. Chan, Jianjun Yu, Mike Doyle, P. Feucht, R. Warne, Jamie Narberes, Tiffany Tsang, C. Fritsch, A. Kauffmann, E. Pfister, P. Drueckes, J. Trappe, Christopher Wilson, W. Han, Jiong Lan, G. Nishiguchi, M. Lindvall, C. Bellamacina, J. Aycinena, Richard Zang, J. Holash, M. Burger (2014)
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic CancersClinical Cancer Research, 20
L. Campos, J. Rouault, O. Sabido, P. Oriol, N. Roubi, C. Vasselon, E. Archimbaud, J. Magaud, D. Guyotat (1993)
High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.Blood, 81 11
C. Röllig, H. Serve, A. Hüttmann, R. Noppeney, C. Müller-Tidow, U. Krug, C. Baldus, C. Brandts, V. Kunzmann, H. Einsele, A. Krämer, K. Schäfer-Eckart, A. Neubauer, A. Burchert, Aristoteles Giagounidis, S. Krause, A. Mackensen, W. Aulitzky, R. Herbst, M. Hänel, A. Kiani, N. Frickhofen, J. Kullmer, U. Kaiser, H. Link, T. Geer, A. Reichle, C. Junghanss, R. Repp, F. Heits, H. Dürk, Jana Hase, Ina-Maria Klut, T. Illmer, M. Bornhäuser, M. Schaich, S. Parmentier, M. Görner, C. Thiede, M. Bonin, J. Schetelig, M. Kramer, W. Berdel, G. Ehninger (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.The Lancet. Oncology, 16 16
Michele Palma, D. Hanahan (2012)
The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilitiesMolecular Oncology, 6
Anna Brown, C. Hahn, H. Scott (2020)
Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).Blood
Y. Tabe, Linhua Jin, Y. Tsutsumi‐Ishii, Yuanyuan Xu, T. McQueen, W. Priebe, G. Mills, A. Ohsaka, I. Nagaoka, M. Andreeff, M. Konopleva (2007)
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.Cancer research, 67 2
G. Issa, C. Dinardo (2021)
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithmBlood Cancer Journal, 11
J. Cornelissen, D. Breems, W. Putten, A. Gratwohl, Jakob Passweg, T. Pabst, J. Maertens, H. Beverloo, M. Kooy, P. Wijermans, B. Biemond, E. Vellenga, L. Verdonck, G. Ossenkoppele, B. Löwenberg (2012)
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 17
Mrinal Shah, J. Licht (2011)
DNMT3A mutations in acute myeloid leukemiaNature Genetics, 43
C. Récher, O. Beyne-Rauzy, C. Demur, G. Chicanne, Cedric Santos, V. Mas, D. Benzaquen, G. Laurent, F. Huguet, B. Payrastre (2005)
Antileukemic activity of rapamycin in acute myeloid leukemia.Blood, 105 6
G. Marcucci, K. Maharry, Yue-zhong Wu, M. Radmacher, K. Mrózek, D. Margeson, Kelsi Holland, S. Whitman, H. Becker, S. Schwind, K. Metzeler, B. Powell, T. Carter, J. Kolitz, M. Wetzler, A. Carroll, M. Baer, M. Caligiuri, R. Larson, C. Bloomfield (2010)
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 14
J. Lipof, K. Loh, K. O'Dwyer, J. Liesveld (2018)
Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid LeukemiaCancers, 10
J. Welch, T. Ley, D. Link, Christopher Miller, D. Larson, D. Koboldt, L. Wartman, T. Lamprecht, Fulu Liu, Jun Xia, C. Kandoth, R. Fulton, M. McLellan, D. Dooling, J. Wallis, Ken Chen, C. Harris, Heather Schmidt, Joelle Kalicki-Veizer, Charles Lu, Qunyuan Zhang, Ling Lin, M. O'Laughlin, Joshua McMichael, K. Delehaunty, L. Fulton, V. Magrini, S. McGrath, Ryan Demeter, T. Vickery, J. Hundal, L. Cook, Gary Swift, Jerry Reed, Patricia Alldredge, T. Wylie, Jason Walker, M. Watson, S. Heath, W. Shannon, Nobish Varghese, R. Nagarajan, J. Payton, J. Baty, S. Kulkarni, J. Klco, M. Tomasson, P. Westervelt, M. Walter, T. Graubert, J. Dipersio, L. Ding, E. Mardis, R. Wilson (2012)
The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 150
M. Heuser, S. Freeman, G. Ossenkoppele, F. Buccisano, C. Hourigan, L. Ngai, J. Tettero, C. Bachas, C. Baer, A. Czyż, B. Denys, R. Dillon, M. Feuring‐Buske, M. Guzman, T. Haferlach, Lina Han, J. Herzig, J. Jorgensen, W. Kern, M. Konopleva, F. Lacombe, M. Libura, Agata Majchrzak, L. Maurillo, Y. Ofran, J. Philippé, A. Plesa, C. Preudhomme, F. Ravandi, C. Roumier, M. Subklewe, F. Thol, A. Loosdrecht, B. Reijden, A. Venditti, A. Wierzbowska, P. Valk, B. Wood, R. Walter, C. Thiede, G. Roboz, J. Cloos (2021)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Hae-Jung Park, M. Gregory, Vadym Zaberezhnyy, A. Goodspeed, C. Jordan, J. Kieft, J. DeGregori (2022)
Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylationeLife, 11
A. Burnett, M. Wetzler, B. Löwenberg (2011)
Therapeutic advances in acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 5
Bei Liu, Lijun Li, Xia Gong, Wei Zhang, Hui Zhang, Li Zhao (2018)
Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myeloid leukemia.Oncology letters, 15 5
Sampa Gupta, H. Baumann, M. Wetzler (2008)
Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia.Leukemia research, 32 7
P. Montesinos, C. Récher, S. Vives, E. Zarzycka, Jianxiang Wang, Giambattista Bertani, M. Heuser, R. Calado, A. Schuh, S. Yeh, S. Daigle, J. Hui, S. Pandya, D. Gianolio, S. Botton, H. Döhner (2022)
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.The New England journal of medicine, 386 16
Ping Chen, Huifang Huang, Juanying Wu, R. Lu, Yong Wu, Xi Jiang, Q. Yuan, Yuanzhong Chen (2015)
Bone marrow stromal cells protect acute myeloid leukemia cells from anti‐CD44 therapy partly through regulating PI3K/Akt–p27Kip1 axisMolecular Carcinogenesis, 54
J. Cortes, A. Perl, H. Döhner, H. Kantarjian, G. Martinelli, T. Kovacsovics, P. Rousselot, B. Steffen, H. Dombret, E. Estey, S. Strickland, J. Altman, C. Baldus, A. Burnett, A. Krämer, N. Russell, N. Shah, Catherine Smith, E. Wang, N. Ifrah, G. Gammon, D. Trone, D. Lazzaretto, M. Levis (2018)
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.The Lancet. Oncology, 19 7
E. Keeton, K. McEachern, K. Dillman, Sangeetha Palakurthi, Yichen Cao, M. Grondine, S. Kaur, Suping Wang, YuChing Chen, Allan Wu, Minhui Shen, F. Gibbons, M. Lamb, Xiaolan Zheng, R. Stone, D. DeAngelo, L. Platanias, L. Dakin, Huawei Chen, P. Lyne, D. Huszar (2014)
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.Blood, 123 6
S. Sriskanthadevan, D. Jeyaraju, T. Chung, S. Prabha, Wei Xu, M. Škrtić, Bozhena Jhas, R. Hurren, M. Gronda, Xiaoming Wang, Y. Jitkova, M. Sukhai, Fengshu Lin, N. Maclean, R. Laister, C. Goard, P. Mullen, Stephanie Xie, L. Penn, I. Rogers, J. Dick, M. Minden, A. Schimmer (2015)
AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress.Blood, 125 13
G. Ossenkoppele, G. Schuurhuis (2016)
MRD in AML: does it already guide therapy decision-making?Hematology. American Society of Hematology. Education Program, 2016 1
Catherine Smith, Chao Zhang, Kimberly Lin, E. Lasater, Ying Zhang, E. Massi, L. Damon, Matthew Pendleton, A. Bashir, R. Sebra, A. Perl, A. Kasarskis, Rafe Shellooe, Garson Tsang, Heidi Carias, Ben Powell, Elizabeth Burton, Bernice Matusow, Jiazhong Zhang, W. Spevak, P. Ibrahim, M. Le, H. Hsu, G. Habets, B. West, G. Bollag, N. Shah (2015)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.Cancer discovery, 5 6
T. Boyer, Fanny Gonzales, Adeline Barthélémy, A. Marceau-Renaut, P. Peyrouze, S. Guihard, P. Lepelley, A. Plesa, O. Nibourel, C. Delattre, M. Wetterwald, N. Pottier, I. Plantier, S. Botton, H. Dombret, C. Berthon, C. Preudhomme, C. Roumier, M. Cheok (2019)
Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive StudyCancers, 11
S. Wander, M. Levis, A. Fathi (2014)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyondTherapeutic Advances in Hematology, 5
E. Stein, C. Dinardo, A. Fathi, A. Mims, K. Pratz, M. Savona, A. Stein, R. Stone, E. Winer, C. Seet, H. Döhner, D. Pollyea, J. Mccloskey, O. Odenike, B. Löwenberg, G. Ossenkoppele, P. Patel, M. Roshal, M. Frattini, F. Lersch, A. Franovic, S. Nabhan, Bin Fan, S. Choe, Hongfang Wang, Bin Wu, L. Hua, Caroline Almon, Michael Cooper, H. Kantarjian, M. Tallman (2020)
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.Blood
V. Salama, N. Brooks, Anna Skwarska, L. Kays, P. Milligan, K. Newell, K. Roth, S. Geeganage, R. Gilmour, Steven Chan, J. Sarry, M. Sabatier, C. Dinardo, M. Konopleva (2020)
Abstract 6417: LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)Cancer Research, 80
D. Thompson, D. Moore (2020)
Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid LeukemiaJournal of the Advanced Practitioner in Oncology, 11
Prior to the past few years, the development of new therapies for acute myeloid leukemia (AML) has been disappointingly slow. For several decades, the standard therapy for AML has consisted of intensive induction chemotherapy, and potentially a subsequent hematopoietic stem cell transplant. Unfortunately, older patients are less responsive to, and are frequently unfit to tolerate, such intensive chemotherapy. Given that a majority of AML patients are elderly, this population has been most affected by the lack of newer less toxic therapies. However, in recent years, the treatment landscape for AML has dramatically shifted with the approval of many new drugs. As summarized in this review, several of these new drugs are targeted agents that are better tolerated than standard chemotherapy and could substantially benefit elderly patients. Although drug resistance remains a major concern, the treatment options for elderly AML patients are more numerous than ever before, bringing new promise for improved patient outcomes.
Aging and Cancer – Wiley
Published: Jun 1, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.